Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours an...
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expec...
* Pome project schedule delayed * Lower-than-expected project margins in Pome and Pienava * We cut '...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
* Orders -10%, sales +3%, adj. EBITA -6% vs. ABGSCe * Enedo drove EBITA miss, Inission beat; Enedo b...
Redeye provides an update following Corline’s Q2 2025 report.
* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...
* Q2 beat with activity picking up * Pre-tax profit up by 13-16% for 2026-27e * 2025e-27e EV/EBIT of...
* '25e-'27e sales cut by 6-1% * Market softness persists, delaying customer decisions * Cost-cutting...
Redeye provides a research update following the Q2 report published by Isofol earlier today.
Redeye provides an initial take following the release of Corline’s Q2 2025 report.
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
